Improved synthesis of the bifunctional chelating agent 1,4,7,10- tetraaza-N-(1-carboxy-3-(4-nitrophenyl)propyl)-N',N'',N'''-tris(acetic acid)cyclododecane (PA-DOTA)

Lara L. Chappell, Buck E. Rogers, M. B. Khazaeli, Matthew S. Mayo, Donald J. Buchsbaum, Martin W. Brechbiel

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Abstract

A concise synthesis of the bifunctional chelating agent 1,4,7,10- tetraaza-N-(1-carboxy-3-(4-nitrophenyl)propyl)-N','',N'''-tris(acetic acid)cyclododecane (PA-DOTA) is reported. Difficulties involving the production of partially alkylated products and their removal have been addressed and obviated. After the pure nitro form of PA-DOTA was obtained, conversion to the isothiocyanato form PA-DOTA (1, conjugation to HuCC49 and HuCC49ΔCH2 monoclonal antibodies was achieved. Subsequent radiolabeling with 177Lu was performed, demonstrating a useful bifunctional chelating agent suitable for clinical radioimmunotherapy applications. (C) 1999 Published by Elsevier Science Ltd.

Original languageEnglish
Pages (from-to)2313-2320
Number of pages8
JournalBioorganic and Medicinal Chemistry
Volume7
Issue number11
DOIs
StatePublished - Nov 1999

Keywords

  • Biodistribution
  • DOTA
  • Lutetium-177
  • Radioimmono-conjugate

Fingerprint

Dive into the research topics of 'Improved synthesis of the bifunctional chelating agent 1,4,7,10- tetraaza-N-(1-carboxy-3-(4-nitrophenyl)propyl)-N',N'',N'''-tris(acetic acid)cyclododecane (PA-DOTA)'. Together they form a unique fingerprint.

Cite this